| Project/Area Number |
23790490
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Bacteriology (including Mycology)
|
|---|
| Research Institution | National Institute of Infectious Diseases |
|---|
Principal Investigator |
HONDA Naoko 国立感染症研究所, 品質保証・管理部, 研究員 (40600911)
|
|---|
| Project Period (FY) |
2011-04-28 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2013: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2012: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 結核 / ストレプトマイシン / 休眠 / 抗酸菌 / ストレプトマイシン要求性 / 再燃 / 細菌 |
|---|
| Outline of Final Research Achievements |
A SM dependent mutant M. tuberculosis 18b strain has an additional cytosine residue in 16S rRNA and this mutation has been considered to be responsible for SM dependence. As 18b strain replicates in SM containing medium and enters non-replicating state after SM removal even in aerobic cultures, this has been developed as dormancy model to screen new drugs active against non-replicating state in recent years. As BSL3 facility is required to culture 18b and it is not known whether other mutations associated with drug susceptivity exist on 18b, we introduced the same nucleotide insertion on the currently used vaccine strain, M. bovis BCG Tokyo and confirmed that this mutation conferred SM dependence. We further examined the effect of first line drugs on non-replicating SM starved BCG and showed that this strain had phenotypic resistance to isoniazid and will be useful for screening of new drugs in BSL2 facilities.
|
